Vera Therapeutics Provides Business Update and Reports Second Quarter Financial ResultsGlobeNewsWire • 08/10/23
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) CongressGlobeNewsWire • 06/17/23
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgANGlobeNewsWire • 06/15/23
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts sayMarket Watch • 06/12/23
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/08/23
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)GlobeNewsWire • 06/07/23
Vera Therapeutics Provides Business Update and Reports First Quarter Financial ResultsGlobeNewsWire • 05/11/23
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/28/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERAPRNewsWire • 02/07/23
Vera Therapeutics Announces Pricing of Public Offering of Class A Common StockGlobeNewsWire • 02/02/23
Vera Therapeutics Announces Commencement of Public Offering of Class A Common StockGlobeNewsWire • 02/01/23
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in ProteinuriaGlobeNewsWire • 01/30/23
5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)Benzinga • 01/13/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 01/12/23